I wouldn't call today's PR a negative, but just not much of a positive.
Short-term,.... absolutely on the mark JG,.... and since that is what the market has to look at as regards NNVC,... the 'meehhh!' response for the day to the announcement.
Just another candidate drug (if an extremely promising one with a huge downstream revenue generation potential) in the pipeline.
Problem (of course) being the lack of revenue-generation from the drugs already moving down that same pipeline to grease the skids.
Long-term,.... the potential is huge. But it remains only 'potential' for the time being,....
News 
Market Data 
Discover 
